Clinical validation ExThera Medical is actively pursuing randomized controlled trials for the Seraph 100 device to treat sepsis from wound infections, signaling a need for clinical partners, site coordinators, and payer engagement to support trial enrollment and eventual adoption.

Strategic partnerships Recent collaborations with Trusted Health Advisors and a new client in MTEC funding suggest opportunities to co-market with clinical experts, expand oncology initiatives, and leverage advisory networks to accelerate sales and adoption in hospital settings.

Leadership signals CEO appointment and CFO addition in 2023 indicate a maturing organization with governance and financing capabilities, presenting a compelling case to risk-tolerant buyers and finance teams for procurement cycles and long-term contracts.

Innovation awards Edison Award Gold and BioMedSA recognition underscore proven innovation and regulatory-grade potential, which can be leveraged in sales pitches to govern ment, hospital systems, and procurement committees seeking validated technology.

Market positioning Product focus on broad-spectrum hemoperfusion for severe infections and metastatic cancer positions ExThera to engage acute care networks, infectious disease teams, and oncology/support services seeking extracorporeal filtration solutions with strong clinical narratives.